Schizophrenia

The oral combination therapy can also be used as acute treatment for manic or mixed episodes.

Approximately 30% of schizophrenia patients do not respond to their first treatment.

Clozapine is considered the gold standard of schizophrenia treatment.

Education could be the best resource in increasing prescription rates for clozapine.

New data show high rate of depressive symptoms in patients with NTFE schizophrenia.

New data show adverse childhood experiences can cause personality changes proximal to trauma, rather than developing later in life.

While treatment options do not impact 30-day readmissions, they can influence hospital length of stay and costs.

In a poster presented at APA, researchers review current clinical practice guidelines for schizophrenia.

Henry Nasrallah, MD, discusses patient factors that lead to long-acting injectable treatment in patients with schizophrenia.  

Henry Nasrallah, MD, recalls the history behind long-acting injectables in patients with schizophrenia.

A panel of experts in psychiatric treatment review the burden schizophrenia has on the health care system.

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, explain how to increase patient adherence to treatment and address the stigma associated with schizophrenia even in the family of the patient.

Henry Nasrallah, MD, examines schizophrenia relapse, specifically how to diagnose and prevent it before further damage has transpired in the patient’s brain.  

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, discuss the challenges and unmet needs psychiatrists and their teams face when treating patients with schizophrenia and their multiple comorbidities.

Joe Avelino, RN, BSN, MHSA, CPHQ, and Henry Nasrallah, MD, review schizophrenia and the needs of these patients.

Researchers find higher neurocognitive abilities are associated with an improvement of everyday life.

A higher percentage of patients suffering from a severe mental disorder such as schizophrenia or bipolar disorder, died from a COVID-19 infection than the control group.

Individuals diagnosed with mood or anxiety disorders were not linked to higher COVID-19 mortality.

Experts expect more individuals to face mental health challenges caused by the events of 2020.

Repeated Transcranial Magnetic Stimulation shows more efficacy treating bipolar disorder than schizophrenia.

The lipid profile changes were not significant after 6 months, while the changes in the lipid profile are due to other factors and not the drugs.

The first-line atypical antipsychotic was linked to better outcomes in patients than comparators aripiprazole and olanzapine.